BioClinica Names Dr. John Hubbard Chief Executive Officer

NEWTOWN, Pa. -- BioClinica®, Inc., a leading provider of specialty outsourced clinical trial services, announced today that it has appointed John Hubbard, Ph.D., FCP, as chief executive officer and a member of the board of directors.  A seasoned pharmaceutical executive, Dr. Hubbard, 58, will join the company from Pfizer Inc., where he has served as senior vice president and worldwide head of development operations.  Dr. Hubbard will assume the CEO position on January 5, 2015 from Mark Weinstein.

"John is ideally suited to lead BioClinica.  His breadth of experience in virtually every aspect of the drug development process gives him a unique understanding of our customers' needs, and how BioClinica can support them in efficiently managing the complexities of their trials," said Jeffrey McMullen, chairman, BioClinica.

He added, "On behalf of the board, I'd like to thank Mark for his years of service to BioClinica.  He has done an outstanding job of bringing together BioClinica and CCBR-SYNARC's capabilities following their merger earlier this year.  The company is strongly positioned to offer customers a comprehensive suite of clinical trial solutions, including imaging services, patient recruitment, cardiac safety and eClinical services."

During his 30-year career, Dr. Hubbard has spearheaded pharmaceutical research and development initiatives for some of the industry's premier organizations.  At Pfizer, he was responsible for more than 450 Phase 1-4 clinical projects per year.  He also served on the taskforce that redesigned Pfizer's research and development organization.  Prior to Pfizer, Dr. Hubbard was group president of ICON plc's clinical research services business, the company's largest business division. During his tenure, ICON was named one of the country's fastest growing companies by FORTUNE.  Dr. Hubbard also has held management positions at PAREXEL International Corporation, Revlon Health Care Group and Hoechst Marion Roussel Pharmaceuticals (now owned by Sanofi).

"I am delighted to become part of the BioClinica organization.  We have a unique opportunity to partner with pharmaceutical companies and contract research organizations as they navigate unprecedented pressures, which I have experienced firsthand, and to improve the efficiency and effectiveness of drug development," said Dr. Hubbard.  "BioClinica has exceptional scientific acumen, sophisticated technologies and specialized services that I believe will be instrumental in helping customers overcome these challenges and achieving their goals for bringing new products to market."

Dr. Hubbard is a member of the Society of Clinical Pharmacology and Therapeutics, Drug Information Association and has served on its Special Interest Advisory Committee on Project Management.  He is a board certified diplomat in applied pharmacology and was elected as a fellow of the American College of Clinical Pharmacology (ACCP).  Dr. Hubbard has authored and co-authored articles and chapters on biopsychology, cardiovascular, clinical pharmacology and global drug development.  He received his bachelor's degree in biopsychology from the University of Santa Clara and a doctorate from the University of Tennessee.  Dr. Hubbard was a National Institute of Health postdoctoral fellow in cardiovascular and clinical pharmacology at the University of Texas Health Sciences Center.

About BioClinica, Inc. BioClinica accelerates the development of new medical therapies by delivering expertise and technologies that enhance clinical research, worldwide. Our industry-leading medical imaging services, cardiac safety, patient recruitment and management, and enterprise eClinical platform bring a new level of quality and efficiency to every phase of clinical development. Our experience spans three decades and includes thousands of studies in all therapeutic areas, from design and management, through submission and post-approval. BioClinica serves more than 400 pharmaceutical, biotechnology, and device companies – including all the top 20 - through a network of offices in the U.S., Europe and Asia.